Spots Global Cancer Trial Database for advanced solid malignancies
Every month we try and update this database with for advanced solid malignancies cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| A Phase I Study of Fluzoparib in Patient With Advanced Solid Malignancies | NCT02575651 | Advanced Solid ... | Fluzoparib | 18 Years - 70 Years | Jiangsu HengRui Medicine Co., Ltd. | |
| A Study of Repotrectinib (TPX-0005) in Patients With Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements | NCT03093116 | Locally Advance... Metastatic Soli... | Oral repotrecti... | 12 Years - | Turning Point Therapeutics, Inc. | |
| Study of AZD8931 in Patients With Advanced Solid Malignancies | NCT00637039 | Advanced Solid ... | AZD8931 | 18 Years - | AstraZeneca | |
| Study of AZD9574 as Monotherapy and in Combination With Anti-cancer Agents in Participants With Advanced Solid Malignancies | NCT05417594 | Advanced Solid ... | AZD9574 Temozolomide [11C]AZ1419 339... Datopotamab Der... Trastuzumab Der... | 18 Years - 130 Years | AstraZeneca | |
| Study to Assess the Safety, Tolerability, Pharmacokinetics (PK) and Preliminary Efficacy of AZD2014 | NCT01026402 | Advanced Solid ... | AZD2014 | 18 Years - 150 Years | AstraZeneca | |
| Clinical Trial to Evaluate Safety and Tolerability of OratecanTM in Patients With Advanced Solid Malignancies (Oratecan-102) | NCT00986843 | Advanced Solid ... | HM30181AK table... | 19 Years - | Hanmi Pharmaceutical Company Limited | |
| A Phase I Study, Evaluating the Safety, Pharmacokinetics and Efficacy of PRJ1-3024 in Subjects With Advanced Solid Tumors | NCT05159700 | Advanced Solid ... Advanced Solid ... | PRJ1-3024 | 18 Years - | Zhuhai Yufan Biotechnologies Co., Ltd | |
| 10mg ZD4054 (Zibotentan) PK Study in Male, Elderly Chinese Patients With Advanced Solid Malignancies | NCT00997945 | Advanced Solid ... | ZD4054 (Ziboten... | 50 Years - | AstraZeneca | |
| Study to Assess Safety and Tolerability of AZD0530 in Combination With Carboplatin and Paclitaxel | NCT01000896 | Cancer Non Small Cell ... Epithelial Ovar... | AZD0530 Carboplatin paclitaxel | 20 Years - | AstraZeneca | |
| A Study of Safety and Efficacy of KFA115 Alone and in Combination With Pembrolizumab in Patients With Select Advanced Cancers | NCT05544929 | Carcinoma, Non-... Cutaneous Melan... Carcinoma, Rena... Carcinoma, Ovar... Nasopharyngeal ... Carcinoma, Thym... Anal Cancer Mesothelioma Esophagogastric... High Microsatel... Squamous Cell C... Triple Negative... | KFA115 pembrolizumab | 18 Years - | Novartis | |
| A Study of BMS-663513 Administered in Combination With Chemotherapy to Subjects With Advanced Solid Malignancies | NCT00351325 | Advanced Solid ... | BMS-663513 | 18 Years - | Bristol-Myers Squibb | |
| An Open-Label Phase 1 Study of Ceralasertib in Japanese Patients With Advanced Solid Malignancies | NCT05469919 | Advanced Solid ... | Ceralasertib | 18 Years - | AstraZeneca | |
| Dose-escalation Study to Assess Safety, Tolerability and Pharmacokinetics of MEDI-573 in Japanese Subjects | NCT01340040 | Cancer Advanced Solid ... | MEDI-573 | 18 Years - | AstraZeneca | |
| Study of Satraplatin With Capecitabine to Treat Advanced Solid Malignancies | NCT00329329 | Malignancies | satraplatin and... | 18 Years - | Agennix | |
| A Trial to Determine the Maximum Tolerated Dose and Evaluate the Safety and Pharmacokinetics of Docetaxel-PNP, Polymeric Nanoparticle Formulation of Docetaxel, in Subjects With Advanced Solid Malignancies | NCT01103791 | Advanced Solid ... | Docetaxel-PNP | 18 Years - | Samyang Biopharmaceuticals Corporation | |
| Phase I, Open-label, Dose-escalation, Safety and PK Study of AZD6918 | NCT00733031 | Cancer, Solid Tumors Advanced Solid ... | AZD6918 gemcitabine pemetrexed | 18 Years - | AstraZeneca | |
| A Study of Amivantamab Subcutaneous (SC) Administration for the Treatment of Advanced Solid Malignancies | NCT04606381 | Advanced Solid ... | Ami-LC-MD Ami-LC Ami-HC Ami-HC-CF Lazertinib | 18 Years - | Janssen Research & Development, LLC | |
| A Phase I Study of MEDI9447 (Oleclumab) in Japanese Patients | NCT03736473 | Advanced Solid ... | MEDI9447 (olecl... | 20 Years - | AstraZeneca | |
| A Study of Amivantamab Subcutaneous (SC) Administration for the Treatment of Advanced Solid Malignancies | NCT04606381 | Advanced Solid ... | Ami-LC-MD Ami-LC Ami-HC Ami-HC-CF Lazertinib | 18 Years - | Janssen Research & Development, LLC | |
| Evaluate Safety, Tolerability, PK, Preliminary Clinical Activity of OB318 in Patients With Advanced Solid Malignancies | NCT02347228 | Advanced Solid ... | OB318 capsule | 20 Years - | Oneness Biotech Co., Ltd. | |
| A Phase I/II Study to Evaluate the Safety, Pharmacokinetics and Efficacy of PRJ1-3024 in Subjects With Advanced Solid Tumors | NCT05315167 | Advanced Solid ... Advanced Solid ... | PRJ1-3024 | 18 Years - | Zhuhai Yufan Biotechnologies Co., Ltd | |
| A Phase I Study of Fluzoparib in Patient With Advanced Solid Malignancies | NCT02575651 | Advanced Solid ... | Fluzoparib | 18 Years - 70 Years | Jiangsu HengRui Medicine Co., Ltd. | |
| A Phase I Open-label Study for Subjects With Advanced Malignancies | NCT04136834 | Advanced Solid ... | PT01 (Pegtomarg... | 18 Years - | Athenex, Inc. | |
| Absorption, Distribution, Metabolism and Excretion (ADME) Study of TKI258 in Patients With Advanced Solid Malignancies | NCT00669097 | Advanced Solid ... | TKI258 | 18 Years - | Novartis | |
| Analysis of Pharmacodynamic Changes With AUY922A, an HSP90 Inhibitor | NCT01024283 | Advanced Solid ... | 16 Years - | Royal Marsden NHS Foundation Trust | ||
| An Open-Label, Multi-Centre, Study to Assess the Safety of Fixed-Dose Durvalumab + Tremelimumab Combination Therapy or Durvalumab Monotherapy in Advanced Solid Malignancies. | NCT03084471 | Advanced Solid ... | MEDI4736 (Durva... MEDI4736 (Durva... | 18 Years - 130 Years | AstraZeneca | |
| A Dose Escalation Study to Assess the Safety and Tolerability of HMPL-453 in Patients With Advanced Solid Malignancies | NCT02966171 | Solid Tumor | HMPL-453 | 25 Years - | Hutchmed | |
| A Phase I/II Study to Evaluate the Safety, Pharmacokinetics and Efficacy of PRJ1-3024 in Subjects With Advanced Solid Tumors | NCT05315167 | Advanced Solid ... Advanced Solid ... | PRJ1-3024 | 18 Years - | Zhuhai Yufan Biotechnologies Co., Ltd | |
| A Dose Escalation Study in Adult Patients With Advanced Solid Malignancies | NCT01004224 | Advanced Solid ... Squamous Lung C... Bladder Cancer ... Advanced Solid ... Advanced Solid ... Advanced Solid ... | BGJ398 | 18 Years - | Novartis | |
| A Study of MEDI-575 in Patients With Advanced Solid Malignancies | NCT01102400 | Advanced Solid ... | MEDI-575 | 20 Years - | AstraZeneca | |
| Study of AZD9150 and MEDI4736 (Durvalumab) in Japanese Adult Patients With Advanced Solid Malignancies | NCT03394144 | Advanced Solid ... | AZD9150, Durval... | 20 Years - 120 Years | AstraZeneca | |
| Phase I, Open-Label, Dose-Escalation Study of AZD4877 in Solid Tumors | NCT00389389 | Neoplasms | AZD4877 | 18 Years - | AstraZeneca | |
| Study of Satraplatin With Capecitabine to Treat Advanced Solid Malignancies | NCT00329329 | Malignancies | satraplatin and... | 18 Years - | Agennix | |
| Study of L-NDDP (Aroplatin) in Patients With Advanced Solid Malignancies or B-Cell Lymphoma | NCT00316511 | Malignancies B-Cell Lymphoma | Aroplatin | 18 Years - | Agenus Inc. | |
| Ipilimumab (Immunotherapy) and MGN1703 (TLR Agonist) in Patients With Advanced Solid Malignancies | NCT02668770 | Advanced Cancer... Melanoma | MGN1703 Ipilimumab | 18 Years - | M.D. Anderson Cancer Center | |
| Global Phase1 Study to Assess the Safety and Tolerability of AZD1208 in Advanced Solid Tumors and Malignant Lymphoma | NCT01588548 | Advanced Solid ... Malignant Lymph... | AZD1208 | 18 Years - 130 Years | AstraZeneca | |
| A Study to Determine the Pharmacokinetics of Cediranib in Chinese Patients With Advanced Solid Malignancies | NCT00981721 | Advanced Solid ... | cediranib (RECE... | 18 Years - | AstraZeneca | |
| A Phase Ib/II Study of the Combination of BYL719 Plus AMG 479 in Adult Patients With Selected Solid Tumors | NCT01708161 | PIK3CA Mutated ... PIK3CA Amplifie... | BYL719 AMG 479 | 18 Years - | Novartis | |
| Japanese Phase I Study of AZD2014 in Advanced Solid Malignancies | NCT02398747 | Advanced Solid ... | AZD2014 | 20 Years - 80 Years | AstraZeneca | |
| A Study of Repotrectinib (TPX-0005) in Patients With Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements | NCT03093116 | Locally Advance... Metastatic Soli... | Oral repotrecti... | 12 Years - | Turning Point Therapeutics, Inc. | |
| Study of AZD8931 in Patients With Advanced Solid Malignancies | NCT00637039 | Advanced Solid ... | AZD8931 | 18 Years - | AstraZeneca | |
| Study to Assess the Safety and Tolerability of the Tor Kinase Inhibitor AZD8055 | NCT00973076 | Cancer Solid Tumors Advanced Solid ... | AZD8055 | 20 Years - | AstraZeneca | |
| A Study of Amivantamab Subcutaneous (SC) Administration for the Treatment of Advanced Solid Malignancies | NCT04606381 | Advanced Solid ... | Ami-LC-MD Ami-LC Ami-HC Ami-HC-CF Lazertinib | 18 Years - | Janssen Research & Development, LLC | |
| Clinical Trial to Evaluate Safety and Tolerability of OratecanTM in Patients With Advanced Solid Malignancies (Oratecan-102) | NCT00986843 | Advanced Solid ... | HM30181AK table... | 19 Years - | Hanmi Pharmaceutical Company Limited | |
| A Study of BMS-663513 Administered in Combination With Chemotherapy to Subjects With Advanced Solid Malignancies | NCT00351325 | Advanced Solid ... | BMS-663513 | 18 Years - | Bristol-Myers Squibb | |
| Safety and Efficacy Study of CFI-402411 in Subjects With Advanced Solid Malignancies | NCT04521413 | Advanced Solid ... | CFI-402411 Pembrolizumab | 18 Years - | Treadwell Therapeutics, Inc | |
| Modular Study to Evaluate CT7001 Alone in Cancer Patients With Advanced Malignancies | NCT03363893 | Advanced Solid ... | CT7001 Fulvestrant | 18 Years - | Carrick Therapeutics Limited | |
| A Phase I Dose Escalation Study of Erlotinib in Combination With Theophylline | NCT02080078 | Non-small Cell ... Advanced Solid ... | Theophylline Erlotinib | 18 Years - | AHS Cancer Control Alberta | |
| A Study of Amivantamab Subcutaneous (SC) Administration for the Treatment of Advanced Solid Malignancies | NCT04606381 | Advanced Solid ... | Ami-LC-MD Ami-LC Ami-HC Ami-HC-CF Lazertinib | 18 Years - | Janssen Research & Development, LLC | |
| Dose-escalation Study to Assess Safety, Tolerability and Pharmacokinetics of MEDI-573 in Japanese Subjects | NCT01340040 | Cancer Advanced Solid ... | MEDI-573 | 18 Years - | AstraZeneca | |
| Extended Infusion Carfilzomib on a Weekly Schedule in Patients With Advanced Solid Tumors | NCT02257476 | Neoplasms Malignancies | Carfilzomib Dexamethasone | 18 Years - | Emory University | |
| A Multiple-Ascending-Dose Study of the Safety and Tolerability of REGN421(SAR153192) in Patients With Advanced Solid Malignancies | NCT00871559 | Advanced Solid ... | REGN421(SAR1531... | 18 Years - | Regeneron Pharmaceuticals | |
| Phase I, Dose Study to Look at the Safety and Pharmacokinetics of AZD8835 in Patients With Advanced Solid Tumours | NCT02260661 | Advanced Solid ... Breast Cancer -... Breast Cancer -... | AZD8835 AZD8835 AZD8835 in comb... AZD8835 in comb... | 18 Years - 130 Years | AstraZeneca | |
| Phase1 Study of Gemcitabine HCl Oral Formulation(D07001-F4) in Patients With Advanced Solid Malignancies and Malignant Lymphomas | NCT01800630 | Advanced Solid ... Malignant Lymph... | Gemcitabine HCl... | 20 Years - | InnoPharmax Inc. | |
| SarCaBon: A Randomised Phase II Trial of Saracatinib Versus Placebo for Cancer-induced Bone Pain | NCT02085603 | Cancer | Saracatinib Placebo | 16 Years - | Sheffield Teaching Hospitals NHS Foundation Trust | |
| A Multiple-Ascending-Dose Study of the Safety and Tolerability of REGN421(SAR153192) in Patients With Advanced Solid Malignancies | NCT00871559 | Advanced Solid ... | REGN421(SAR1531... | 18 Years - | Regeneron Pharmaceuticals | |
| A Phase 1 Clinical Study of AZD4635 in Patients With Advanced Solid Malignancies | NCT02740985 | Advanced Solid ... Non-Small Cell ... Metastatic Cast... Colorectal Carc... | AZD4635 Durvalumab Abiraterone Ace... Enzalutamide Oleclumab Docetaxel | 18 Years - 130 Years | AstraZeneca | |
| Study to Assess Safety and Tolerability of AZD0530 in Combination With Carboplatin and Paclitaxel | NCT01000896 | Cancer Non Small Cell ... Epithelial Ovar... | AZD0530 Carboplatin paclitaxel | 20 Years - | AstraZeneca | |
| Phase I, Open-Label, Dose-Escalation Study of AZD4877 in Solid Tumors | NCT00389389 | Neoplasms | AZD4877 | 18 Years - | AstraZeneca | |
| Phase I Single Ascending Dose/Multiple Ascending Dose in Patients Treated With AZD7762 and Irinotecan | NCT00473616 | Advanced Solid ... Cancer Advanced Solid ... | AZD7762 Irinotecan | 18 Years - | AstraZeneca | |
| Ipilimumab and Stereotactic Body Radiation Therapy (SBRT) in Advanced Solid Tumors | NCT02239900 | Liver Cancer Lung Cancer | Ipilimumab Stereotactic Bo... | 18 Years - | M.D. Anderson Cancer Center | |
| Dose-Seeking Study of MPT0E028 in Subjects With Advanced Solid Malignancies Without Standard Treatment | NCT02350868 | Advanced Solid ... | MPT0E028 | 20 Years - | Taipei Medical University | |
| Modular Study to Evaluate CT7001 Alone in Cancer Patients With Advanced Malignancies | NCT03363893 | Advanced Solid ... | CT7001 Fulvestrant | 18 Years - | Carrick Therapeutics Limited | |
| Study to Assess Safety and Tolerability of AZD4547 in Japanese Patient | NCT01213160 | Cancer Advanced Solid ... | AZD4547 | 25 Years - 150 Years | AstraZeneca | |
| Ipilimumab (Immunotherapy) and MGN1703 (TLR Agonist) in Patients With Advanced Solid Malignancies | NCT02668770 | Advanced Cancer... Melanoma | MGN1703 Ipilimumab | 18 Years - | M.D. Anderson Cancer Center | |
| A Study of Safety and Efficacy of KFA115 Alone and in Combination With Pembrolizumab in Patients With Select Advanced Cancers | NCT05544929 | Carcinoma, Non-... Cutaneous Melan... Carcinoma, Rena... Carcinoma, Ovar... Nasopharyngeal ... Carcinoma, Thym... Anal Cancer Mesothelioma Esophagogastric... High Microsatel... Squamous Cell C... Triple Negative... | KFA115 pembrolizumab | 18 Years - | Novartis | |
| Safety and Efficacy Study of CFI-402411 in Subjects With Advanced Solid Malignancies | NCT04521413 | Advanced Solid ... | CFI-402411 Pembrolizumab | 18 Years - | Treadwell Therapeutics, Inc | |
| A Study of HSP990 Administered by Mouth in Adult Patients With Advanced Solid Tumors | NCT00879905 | Advanced Solid ... | HSP990 | 18 Years - | Novartis | |
| A Phase I Study of BR115 for Injection Alone in Subjects With Advanced Solid Malignancies | NCT06388902 | Advanced Solid ... | BR115 for injec... | 18 Years - | BioRay Pharmaceutical Co., Ltd. | |
| Phase I Single Ascending Dose/Multiple Ascending Dose in Patients Treated With AZD7762 and Irinotecan | NCT00473616 | Advanced Solid ... Cancer Advanced Solid ... | AZD7762 Irinotecan | 18 Years - | AstraZeneca | |
| First in Human Phase 1 Study of AG01 Anti-Progranulin/GP88 Antibody in Advanced Solid Tumor Malignancies | NCT05627960 | Triple Negative... Hormone-Resista... Non Small Cell ... Mesothelioma | AG-01 Compound | 18 Years - | A&G Pharmaceutical Inc. | |
| Study of AZD9150 and MEDI4736 (Durvalumab) in Japanese Adult Patients With Advanced Solid Malignancies | NCT03394144 | Advanced Solid ... | AZD9150, Durval... | 20 Years - 120 Years | AstraZeneca | |
| A Study to Evaluate the Safety, Tolerability and How YH002 Enters, Moves Through and Exits the Body in Subjects With Advanced Solid Malignancies | NCT04353102 | Advanced Solid ... | YH002 | 18 Years - | Eucure (Beijing) Biopharma Co., Ltd | |
| Ipilimumab (Immunotherapy) and MGN1703 (TLR Agonist) in Patients With Advanced Solid Malignancies | NCT02668770 | Advanced Cancer... Melanoma | MGN1703 Ipilimumab | 18 Years - | M.D. Anderson Cancer Center | |
| A Phase I/II Study to Evaluate the Safety, Pharmacokinetics and Efficacy of PRJ1-3024 in Subjects With Advanced Solid Tumors | NCT05315167 | Advanced Solid ... Advanced Solid ... | PRJ1-3024 | 18 Years - | Zhuhai Yufan Biotechnologies Co., Ltd | |
| Study of L-NDDP (Aroplatin) in Patients With Advanced Solid Malignancies or B-Cell Lymphoma | NCT00316511 | Malignancies B-Cell Lymphoma | Aroplatin | 18 Years - | Agenus Inc. | |
| Dose-escalation Study to Assess Safety, Tolerability and Pharmacokinetics of MEDI-573 in Japanese Subjects | NCT01340040 | Cancer Advanced Solid ... | MEDI-573 | 18 Years - | AstraZeneca |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
